Literature Analysis (IF 13.7) | AI-Powered Precision Design of Macrocyclic Peptides: Cracking the Code of “Undruggable” Targets
Traditional peptide drug discovery faces major hurdles: heavy reliance on random screening of vast libraries or natural products, inefficient high-throughput processes, and an inability to rationally design stable, high-affinity macrocyclic peptides for “undruggable” targets lacking deep binding pockets.
Macrocyclic peptides offer a promising middle ground between large biologics and small molecules, potentially targeting inaccessible proteins. However, their rational design has remained a key challenge.
This paradigm is now shifting. A team led by Nobel laureate Professor David Baker has introduced RFpeptides, an AI framework published in Nature Chemical Biology. It moves beyond random screening to computationally generate macrocyclic peptides with high target affinity.
Key Advantages of the RFpeptides AI Model
Unprecedented Efficiency
It successfully identified high-affinity binders by testing under 20 designs per target, bypassing the need to screen trillions of candidates.
Precision Targeting
Enables custom design for specific protein sites, unlike non-targeted library methods.
Atomic-Level Accuracy
Allows structure-guided optimization for affinity and properties like cell permeability, streamlining development.
RFpeptides heralds a new era of precision, computational drug design, transforming the process from unpredictable screening to programmable creation.
Leveraging established core platforms for recombinant protein expression and antibody discovery, Alpha Lifetech efficiently supports the requirements for target protein preparation and activity validation essential for AI-driven design. By integrating traditional technologies such as phage display library construction, we have established a complete “AI Design – Experimental Validation – Process Optimization” workflow. This integrated approach provides a one-stop service to tackle “undruggable” targets, covering the entire pipeline from initial design to practical implementation, and facilitates the rapid translation of the RFpeptides technology into tangible research outcomes.